Genscript Biotech Corp. (GNNSF)
1.84
+0.18
(+10.51%)
USD |
OTCM |
Jan 02, 11:36
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.012B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 31.10% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 80.19% |
Profile
| Genscript Biotech Corp. is a holding company, which engages in the manufacture and sale of life sciences research products and services. It operates through the following segments: Bio-science Services and Products; Precision Immune-cell Therapy; and Industrial Synthetic Biology Products. The Bio-science Services and Products segment includes life sciences research services, life sciences research catalogue products, and preclinical drug development services. The Precision Immune-cell Therapy segment discovers and develops therapies for the treatment of liquid tumour through optimised CAR structures and the development of bispecific CAR-T therapies. The Industrial Synthetic Biology Products segment comprises of the construction of non-pathogenic microbial strains and industrial enzyme development and production. The company was founded by Fang Liang Zhang, Lu Quan Wang, and Ye Wang in 2002 and is headquartered in Nanjing, China. |
| URL | http://www.genscript.com |
| Investor Relations URL | N/A |
| HQ State/Province | Jiangsu |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Mar. 12, 2026 (est.) |
| Last Earnings Release | Aug. 18, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 05, 2017 |
Ratings
Profile
| Genscript Biotech Corp. is a holding company, which engages in the manufacture and sale of life sciences research products and services. It operates through the following segments: Bio-science Services and Products; Precision Immune-cell Therapy; and Industrial Synthetic Biology Products. The Bio-science Services and Products segment includes life sciences research services, life sciences research catalogue products, and preclinical drug development services. The Precision Immune-cell Therapy segment discovers and develops therapies for the treatment of liquid tumour through optimised CAR structures and the development of bispecific CAR-T therapies. The Industrial Synthetic Biology Products segment comprises of the construction of non-pathogenic microbial strains and industrial enzyme development and production. The company was founded by Fang Liang Zhang, Lu Quan Wang, and Ye Wang in 2002 and is headquartered in Nanjing, China. |
| URL | http://www.genscript.com |
| Investor Relations URL | N/A |
| HQ State/Province | Jiangsu |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Mar. 12, 2026 (est.) |
| Last Earnings Release | Aug. 18, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 05, 2017 |